GlassScriptPhysician profile
Kimberly Rorick
NPI 1003579004
$3,240.42
in general payments reported to CMS, 2019-2025
23 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,671 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $655.84 | 2024-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $574.83 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $280.95 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $238.86 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.67 | 2024-2025 | Caplyta |
| Abbvie INC. | $204.99 | 2024-2025 | |
| Corium, LLC | $166.68 | 2024-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $150.50 | 2024-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $114.83 | 2024-2025 | Qelbree |
| Arcutis Biotherapeutics, INC. | $105.43 | 2024 | Zoryve |
| Tris Pharma INC | $91.44 | 2024-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $91.37 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $80.58 | 2024-2025 | Uzedy, Austedo Xr |
| Collegium Pharmaceutical, INC. | $39.60 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $37.71 | 2024 | Subvenite |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $36.28 | 2025 | Tms Neurohealth Centers INC. |
| Neos Therapeutics, LP | $31.17 | 2025 | Exxua, Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $26.00 | 2024 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2025 | Trintellix |
| Sage Therapeutics, LLC | $22.56 | 2024 | |
| Tempus Ai, INC | $21.83 | 2024 | |
| Luye Pharma (USA) LTD. | $21.61 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $17.37 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Rorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.